Nxera Pharma, previously known as Sosei Heptares or the Sosei Group, has entered a collaboration and licensing agreement with Antiverse to design antibodies for G-protein coupled receptors (GPCRs).
The multi-target collaboration aims to leverage Antiverse’s expertise in generative AI antibody design, along with its epitope-specific libraries and Nxera’s NxWave platform, to create transformative therapies for various diseases.
Go deeper with GlobalData
Under the multi-year agreement, Antiverse is eligible for an upfront payment and research funding, and qualified for milestone payments.
Nxera will hold an exclusive licence for the antibody assets globally, granting full rights for their development and commercialisation.
The initial project will focus on antibodies’ design with agonistic function for a demanding GPCR target.
Antiverse co-founder and CEO Murat Tunaboylu stated: “Around 220 GPCRs with known disease links are undrugged, and antibodies are an essential tool in our mission to drug them.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“With Nxera’s expertise and support, we are confident our platform can create antibodies for these particularly challenging targets, bringing us closer to creating life-changing therapies for patients.”
Nxera’s NxWave platform serves as a tool for GPCR target selection, validation and structural determination.
The company’s other platform, NxStaR, allows for precise analysis of GPCR structures using techniques such as X-ray crystallography and cryo-electron microscopy.
Nxera Pharma UK president and research and development head Matt Barnes stated: “Our NxWave platform has proven utility in unlocking GPCRs to antibody discovery and combining Nxera’s capabilities with Antiverse’s generative AI antibody design platform enables us to explore this exciting opportunity further, with the aim of developing new biologic therapeutics for multiple diseases, where there is high unmet patient need.”
Antiverse is a techbio company specialising in antibody design for challenging targets, including GPCRs and ion channels.
